First Trust Advisors LP Has $2.85 Million Stake in Omnicell, Inc. $OMCL

First Trust Advisors LP reduced its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 35.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 85,309 shares of the company’s stock after selling 46,411 shares during the quarter. First Trust Advisors LP owned approximately 0.19% of Omnicell worth $2,848,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Omnicell in the 2nd quarter valued at about $26,000. Clearstead Advisors LLC boosted its stake in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after buying an additional 1,218 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in Omnicell during the fourth quarter worth approximately $58,000. Parkside Financial Bank & Trust increased its stake in Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after acquiring an additional 1,264 shares during the period. Finally, First Horizon Corp increased its stake in Omnicell by 54.6% during the 4th quarter. First Horizon Corp now owns 1,597 shares of the company’s stock worth $72,000 after acquiring an additional 564 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on OMCL. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research report on Monday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Omnicell in a research note on Tuesday. Finally, Craig Hallum restated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.86.

Omnicell Stock Performance

NASDAQ:OMCL opened at $36.16 on Friday. The stock has a market cap of $1.64 billion, a P/E ratio of 43.05, a price-to-earnings-growth ratio of 1.01 and a beta of 0.98. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The stock’s 50-day moving average is $41.41 and its 200-day moving average is $40.63. Omnicell, Inc. has a 1-year low of $29.06 and a 1-year high of $55.00.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. During the same quarter last year, the business earned $0.45 EPS. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Insider Buying and Selling at Omnicell

In related news, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the sale, the executive vice president directly owned 154,785 shares in the company, valued at $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $217,180.50. Following the transaction, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by company insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.